company background image
APPH logo

Apontis Pharma XTRA:APPH Stock Report

Last Price

€10.50

Market Cap

€87.5m

7D

2.9%

1Y

132.3%

Updated

18 Jan, 2025

Data

Company Financials +

APPH Stock Overview

Engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. More details

APPH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Apontis Pharma AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Apontis Pharma
Historical stock prices
Current Share Price€10.50
52 Week High€10.60
52 Week Low€4.12
Beta1.23
1 Month Change4.48%
3 Month Change8.70%
1 Year Change132.30%
3 Year Change-38.95%
5 Year Changen/a
Change since IPO-44.00%

Recent News & Updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Oct 17
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Oct 17
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Jun 18
Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

Apr 05
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Shareholder Returns

APPHDE PharmaceuticalsDE Market
7D2.9%0.7%2.6%
1Y132.3%-13.3%13.4%

Return vs Industry: APPH exceeded the German Pharmaceuticals industry which returned -13.3% over the past year.

Return vs Market: APPH exceeded the German Market which returned 13.4% over the past year.

Price Volatility

Is APPH's price volatile compared to industry and market?
APPH volatility
APPH Average Weekly Movement2.4%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: APPH has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: APPH's weekly volatility has decreased from 8% to 2% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1946177Bruno Wohlschlegelapontis-pharma.de

Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany.

Apontis Pharma AG Fundamentals Summary

How do Apontis Pharma's earnings and revenue compare to its market cap?
APPH fundamental statistics
Market cap€87.47m
Earnings (TTM)-€7.08m
Revenue (TTM)€40.63m

2.2x

P/S Ratio

-12.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APPH income statement (TTM)
Revenue€40.63m
Cost of Revenue€15.72m
Gross Profit€24.91m
Other Expenses€31.99m
Earnings-€7.08m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin61.31%
Net Profit Margin-17.42%
Debt/Equity Ratio0%

How did APPH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 04:05
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apontis Pharma AG is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christian OrqueraFirst Berlin Equity Research GmbH
Tim WunderlichHauck Aufhäuser Investment Banking
Alexander GalitsaHauck Aufhäuser Investment Banking